The dissection of intracellular pathways that mediate the inhibitory effects of this receptor are a prerequisite for development of effective small compound inhibitors of LAG‐3 to enhance anti‐tumor responses in cancer patients. The gene discussed is LAG3; the disease is neoplasm.